嵌合抗原受体修饰T细胞研究进展及肿瘤靶抗原的选择

doi:10.16098/j.issn.0529-1356.2017.01.021

摘要/Abstract

摘要：

嵌合抗原受体修饰T细胞（CAR-T）是目前恶性肿瘤免疫治疗的一种新方法。CAR-T细胞对肿瘤的杀伤不依赖主要组织相容性复合体（MHC）,并可克服肿瘤局部免疫抑制微环境和突破宿主免疫耐受状态，因此，CAR-T细胞在治疗肿瘤方面具有独特的优势。CAR-T细胞的构建和选择合适的靶分子是CAR-T细胞免疫治疗的两个关键的问题，我们在文中将围绕这两个问题做一综述。

关键词: 嵌合抗原受体, 肿瘤, 免疫治疗

Abstract:

Chimeric antigen receptor modified T cells (CAR-T) has been an emerging immunotherapy modality for malignant tumor. The cytotoxicity efficiency of CAR-T cells to tumor is independent of the major histocompatibility complex (MHC). CAR-T cells can overcome the immunity suppression in the microenvironmet of the tumor site and break out the immunological tolerance of the host. Thus it has its own advantages in the immunotherapy for tumors. The construction of CAR-T cells and the selection of appropriate tumor target molecules are the two key challengs in CAR-T cell immunotherapy, this review will focus on these two issues.

Key words: Chimeric antigen receptor, Tumor, Immunotherapy

唐海军刘玉琴. 嵌合抗原受体修饰T细胞研究进展及肿瘤靶抗原的选择[J]. 解剖学报, 2017, 48(1): 115-120.

TANG Hai-jun LIU Yu-qin. Development of chimeric antigen receptor modified T cells and the selection of tumor target antigen[J]. Acta Anatomica Sinica, 2017, 48(1): 115-120.

参考文献

［1］Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity［J］. Proc Natl Acad Sci USA, 1989,86(24):10024-10028.

［2］Mazzarella L. Tales from the Jazz ASH: highlights from the 2013 American Society of Haematology meeting［J］. E Cancer Medical Science, 2014,8:390.

［3］Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor modified T cells for acute lymphoid leukemia［J］. N Engl J Med, 2013,368(16):1509-1518.

［4］Kenderian SS, Ruella M, Gill S, et al. Chimeric antigen receptor T-cell therapy to target hematologic malignancies［J］. Cancer Res, 2014,74(22):6383-6389.

［5］Stephan MT, Ponomarev V, Brentjens RJ,et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection［J］. Nat Med,2007, 13(12):1440-1449.

［6］Eshhar Z，Waks T，Gross G，et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors［J］. Proc Natl Acad Sci USA, 1993,90(2):720-724.

［7］Brocker T，Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes［J］. J Exp Med, 1995,181(5):1653-1659.

［8］Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia［J］. N Engl J Med, 2011,365(8):725-733.

［9］Burns WR, Zhao Y, Frankel TL, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas［J］. Cancer Res, 2010,70(8):3027-3033.

［10］Zhao Y, Wang QJ,Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity［J］. J Immunol, 2009,183(9):5563-5574.

［11］Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains［J］. Proc Natl Acad Sci USA, 2009,106(9):3360-3365.

［12］Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2［J］. Mol Ther, 2010,18(4):843-851.

［13］Robbins PF,Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1［J］. J Clin Oncol, 2011, 29(7):917-924.

［14］Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia［J］. Sci Transl Med, 2011,3(95):95ra73.

［15］Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias［J］. Blood, 2011,118(18):4817-4828.

［16］Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells［J］. Blood, 2012,119(12):2709-2720.

［17］Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells［J］. Nat Biotechnol, 2013,31(1):71-75.

［18］Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy［J］. Cancer Gene Ther, 2014,21(2):45-47.

［19］Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives［J］. Nat Rev Clin Oncol, 2012,9(1):16-32.

［20］Xu XJ,Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells［J］. Cancer Lett, 2014,343(2):172-178.

［21］Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect［J］. Blood, 2003,101(4):1637-1644.

［22］Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19［J］. Blood, 2010,116(20):4099-4102.

［23］Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors［J］. Nat Rev Clin Oncol, 2013,10(5):267-276.

［24］Wang CT, Zhang P, Wang YS, et al. RNA- interference against Biot2, a novel mouse testis-specific gene, inhibits the growth of tumor cells［J］. Cell Mol Biol Lett, 2009,14(3):363-376.

［25］Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening［J］. Proc Natl Acad Sci USA, 1997,94(5):1914-1918.

［26］Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered［J］. FEBS J, 2013,280(21):5350-5370.

［27］Choi BD, Suryadevara CM, Gedeon PC, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma［J］. J Clin Neurosci, 2014,21(1):189-190.

［28］Miao H, Choi BD, Suryadevara CM, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma［J］. PLoS One, 2014,9(4):e94281.

［29］Tang X, Zhou Y, Li W, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo［J］. J Biomed Res, 2014,28(6):468-475.

［30］Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice［J］. J Clin Invest, 2010,120(11):3953-3968.

［31］Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia［J］. J Exp Med, 2013,210(6):1125-1135.

［32］Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells［J］. Nat Med, 2013,19(6):747-752.

［33］Lu YC, Yao X, Crystal JS, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions［J］. Clin Cancer Res, 2014,20(13):3401-3410.

［34］Geng W, Zhang ChY, Zhang FQ, et al. Role of cord blood-derived T lymphocytes transplanting for BALB/c mice with erythroleukemia［J］. Acta Anatomica Sinica, 2009, 40(1):57-62. (in Chinese)

耿微，张春燕，张福琴，等. 脐血源性 T淋巴细胞移植在 BALB/c 小鼠红白血病治疗中的作用［J］.解剖学报，2009,40（1）:57-62.

［35］Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia［J］. N Engl J Med, 2014,371(16):1507-1517.

［36］Porter DL，Hwang WT，Frey NV，et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia［J］. Sci Transl Med, 2015,7(303):303.

［37］Ahmed N, Brawley VS, Hegde M,et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma［J］.J Clin Oncol, 2015,33(15):1688-1696.

［38］Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies［J］. Cancer Immunol Res, 2014, 2(2): 112-120.

［39］Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans［J］. Cancer Immunol Res, 2013, 1(1): 26-31.

［40］Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+liver metastases［J］. Clin Cancer Res, 2015, 21(14):3149-3159.

［41］Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity［J］. Mol Ther, 2013,21(4):904-912.

［42］Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells［J］. Front Pharmacol, 2014,5:235.

［43］Davila ML, Kloss CC, Gunset G, et al. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia［J］. PLoS One, 2013,8(4):e61338.

［44］Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia［J］. N Engl J Med, 2013,368(16):1509-1518.

[1]	侯翌葳杨宇王博段英涛姚宏波. 普兰林肽对5×FAD小鼠和WT小鼠认知行为及脑和视网膜β淀粉样蛋白6E10、炎症因子和神经细胞形态的影响[J]. 解剖学报, 2023, 54(3): 283-288.
[2]	张圆时萌萌贺嘉贝吴琼钟小林向宇燕徐杨何洁 . 慢性束缚应激对小鼠海马N6甲基腺苷及相关酶表达的影响[J]. 解剖学报, 2023, 54(2): 142-148.
[3]	张润恒杨翠珠李诗琪王姝涵王欣刘靖马宇昕. 石菖蒲挥发油对炎性痛大鼠脊髓背角中胶质纤维酸性蛋白、c-Jun氨基末端蛋白激酶和肿瘤坏死因子α表达的影响[J]. 解剖学报, 2023, 54(1): 23-29.
[4]	姬光瑜周娟李心悦郝洪波. 多梳家族因子1对结直肠癌干细胞富集的影响及其机制[J]. 解剖学报, 2022, 53(5): 613-619.
[5]	李伟杨赣军彭建安胡红梅周星辰. 低氧化应激下肿瘤坏死因子α过表达对牙髓干细胞生物学性能的影响[J]. 解剖学报, 2022, 53(1): 66-74.
[6]	谭学明赵冉孙永珍高晓炎招鹏王燕朱敏李卫东. 超声内镜精准评估肿瘤起源及组织学特征可提高食管平滑肌瘤的手术疗效[J]. 解剖学报, 2021, 52(6): 966-971.
[7]	苏昊任捷秦丽华. Nogo-B受体在恶性实体肿瘤发病中的抑制和促进作用[J]. 解剖学报, 2021, 52(3): 489-494.
[8]	阴雪妍郭哨恺谭军范文统李明. 腺苷预处理对大鼠脑缺血-再灌注损伤后脑内肿瘤坏死因子α和核因子κB表达的影响[J]. 解剖学报, 2020, 51(6): 839-847.
[9]	吴邢檀梦天覃晓莉洪艳. 神经元素3基因沉默对脐源性胰岛前体细胞MafA表达的影响[J]. 解剖学报, 2020, 51(5): 758-764.
[10]	林晨马琪王萍 . 冠蛋白:肿瘤诊断的潜在靶点[J]. 解剖学报, 2020, 51(3): 461-468.
[11]	刘亚军王旋胡海桂艳. 瑞舒伐他汀预处理对缺血再灌注大鼠大脑中动脉血管平滑肌细胞炎症因子的影响及其机制[J]. 解剖学报, 2019, 50(6): 713-717.
[12]	陈麒黄荷淼葛晨涛付彩云. P物质/神经激肽1受体系统在肿瘤治疗中的研究进展[J]. 解剖学报, 2019, 50(6): 861-864.
[13]	卞晓翠刘玉琴杨振丽冯海凉. 国内建立的人肿瘤细胞系的身份认证问题及对策[J]. 解剖学报, 2019, 50(2): 201-210.
[14]	常书锋杨波郑鲁付战胜杨万敬黄晓峰王俊善刘昌. 枕下乙状窦后锁孔经岩裂-桥脑裂入路的显微解剖学[J]. 解剖学报, 2018, 49(5): 646-650.
[15]	许向亮孙志鹏王佃灿王建伟张卫光. 肿瘤发生相关的腮腺体表分区的临床解剖[J]. 解剖学报, 2018, 49(1): 75-80.